Data & Analytics: New Frontiers for Big Data
Journal Ad Review: Paper Chase
Therapeutic Focus 2014: Metabolic
Specialty Pharma: Coverage at the Crossroads
MAHF 2014: Honoring Our Heroes
MM&M Awards: How to Win
Private View: Telling good brand stories
Read the complete 2014 MM&M Digital Guide digital edition
Bayer and Amgen's Onyx subsidiary announce an oncology drug failed a Phase-III trial goal among liver cancer patients.
A survey of patients found greater prescription drug adherence among patients who received a free 30-day sample in addition to a prescription.
Sanofi and the firm with which it's co-developing alirocumab disclosed that regulators want some patients to be assessed for neurocognitive side effects.
Draftfcb Healthcare has rebranded to FCB Health, and has also acquired UK healthcare agency Halesway, effective immediately, the agency announced today
Healthcare companies are partnering with social entrepreneurs to drive their own agendas on affordability and access while staying at the forefront of global initiatives
Draft guidance indicates the regulator is open to using patient experience as criteria for chronic fatigue syndrome treatments.
The agency's move to limit the formulary for certain drug classes is dead.
The NYT reports that the data on gaming long-term memory is inconclusive.
Click on the image above to see a gallery of images from the 2013 MM&M Awards dinner
The new MM&M e-book, "Oncology Marketing," is designed to serve as a companion for those in the business of communicating cancer products to all three stakeholders. It's packed with analysis, advice, insights and commentary to help navigate the terrain. Click here to access it.